Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Aspire Biopharma Holdings, Inc. - Common Stock (NQ:ASBP)

1.160 -0.150 (-11.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 232,054
Open 1.310
Bid (Size) 1.170 (1,500)
Ask (Size) 1.190 (200)
Prev. Close 1.310
Today's Range 1.140 - 1.310
52wk Range 1.140 - 36.48
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
Via ACCESS Newswire

Performance

YTD
-78.8%
-78.8%
1 Month
-25.2%
-25.2%
3 Month
-68.3%
-68.3%
6 Month
-94.3%
-94.3%
1 Year
-96.6%
-96.6%

More News

Read More
News headline image
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
Via ACCESS Newswire
News headline image
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution
Via ACCESS Newswire
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
Via ACCESS Newswire
News headline image
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
Via ACCESS Newswire
Which stocks are moving on Thursday? ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-01-14: top gainers and losers in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Aspire Biopharma Announces Reverse Stock Split
Via ACCESS Newswire
Most active stocks in Thursday's session ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill
News headline image
ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin –  Retail Expects Licensing Negotiations Soon ↗
Via Stocktwits

Frequently Asked Questions

Is Aspire Biopharma Holdings, Inc. - Common Stock publicly traded?
Yes, Aspire Biopharma Holdings, Inc. - Common Stock is publicly traded.
What exchange does Aspire Biopharma Holdings, Inc. - Common Stock trade on?
Aspire Biopharma Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aspire Biopharma Holdings, Inc. - Common Stock?
The ticker symbol for Aspire Biopharma Holdings, Inc. - Common Stock is ASBP on the Nasdaq Stock Market
What is the current price of Aspire Biopharma Holdings, Inc. - Common Stock?
The current price of Aspire Biopharma Holdings, Inc. - Common Stock is 1.160
When was Aspire Biopharma Holdings, Inc. - Common Stock last traded?
The last trade of Aspire Biopharma Holdings, Inc. - Common Stock was at 03/06/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.